These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27572663)

  • 21. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
    Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y; Miao Y; Yi J; Wang R; Chen L
    Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
    Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
    Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
    Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
    PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.
    Pastuszak-Lewandoska D; Kordiak J; Migdalska-Sęk M; Czarnecka KH; Antczak A; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska D; Brzeziańska-Lasota E
    Respir Res; 2015 Jun; 16(1):76. PubMed ID: 26112163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of 5'-CpG island hypermethylation of the FHIT gene with lung cancer in southern-central Chinese population.
    Li W; Deng J; Jiang P; Tang J
    Cancer Biol Ther; 2010 Nov; 10(10):997-1000. PubMed ID: 20814237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
    Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
    Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma.
    Tomizawa Y; Nakajima T; Kohno T; Saito R; Yamaguchi N; Yokota J
    Cancer Res; 1998 Dec; 58(23):5478-83. PubMed ID: 9850082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Relationship between Occurrence of Liver Cancer and Methylation of Fragile Histidine Triad (FHIT) and P16 Genes.
    Bai Y; Shen Y; Yuan Q; Lv C; Xing Q
    Med Sci Monit; 2019 Feb; 25():1301-1306. PubMed ID: 30773529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
    Su Y; Wang X; Li J; Xu J; Xu L
    Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer.
    Toledo G; Sola JJ; Lozano MD; Soria E; Pardo J
    Mod Pathol; 2004 Apr; 17(4):440-8. PubMed ID: 14976524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer.
    Yu J; Bulk E; Ji P; Hascher A; Tang M; Metzger R; Marra A; Serve H; Berdel WE; Wiewroth R; Koschmieder S; Müller-Tidow C
    Clin Cancer Res; 2010 Apr; 16(8):2275-83. PubMed ID: 20371680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
    Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
    Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Promoter methylation of ASPP1 and ASPP2 genes in non-small cell lung cancers].
    Wei WL; Hu HY; Zhang LJ; Chen Y; Ye E; Wang XF
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):532-6. PubMed ID: 22169642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.
    Lee TG; Jeong EH; Kim SY; Kim HR; Kim H; Kim CH
    Oncotarget; 2017 May; 8(19):31923-31937. PubMed ID: 28404875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
    Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.